In addition, copy number gains on chromosome 9 that include 9p24.1 and elevated expression of PD-L1 within tumor cells have recently been associated with substantial therapeutic activity in patients with advanced or refractory Hodgkin's lymphoma treated with the PD-1 inhibitor nivolumab [27]. Here, CD274 is linked to Hodgkins lymphoma.